The Low-Dose Interleukin-2 in Patients with Stable Ischemic Heart Disease and Acute Coronary Syndromes (LILACS) study was a first-in-class, two-part, randomized, double-blind, placebo-controlled clinical trial that showed the safety and efficacy of IL-2LD in patients with stable ischemic heart disease (Part A) and acute coronary syndrome (ACS) (Part B)10. This evidence concerns the gene IL2 and acute coronary syndrome.